Research & Development
Thermo Fisher Scientific launches CE-IVD marked panel to detect most common gastrointestinal bacteria
With results available in about two hours at greater than 98% sensitivity and specificity, the panel compares favorably with the culturing of samples in a lab, which can take up to two weeks, the firm said.
October 10, 2022
Pharos Capital sells TechLab to SSI Diagnostica
TechLab produces tests for infectious diseases, intestinal inflammation, and parasites, as well as gastrointestinal conditions such as inflammatory bowel disease, irritable bowel syndrome, and Escherichia coli infection. It also offers a test for Clostridioides difficile called Quik Chek, according to Pharos Capital.
August 21, 2022
DiaSorin first-half revenues surge on non-COVID testing
Revenues were driven in part by sales of products from Luminex, acquired last July for $1.8 billion.
August 3, 2022
Guardant touts studies on liquid biopsy tests at ASCO meeting
Data from a large, prospective, observational study shows that Guardant Reveal can detect molecular residual disease (MRD) prior to disease recurrence with an average lead time greater than six months when performed after curative intent surgery for stage II-III colorectal cancer, Guardant said.
January 19, 2022
How will the Quidel, Ortho deal impact the point-of-care market?
The company that can impact the point-of-care market drives the future. The COVID-19 pandemic made that point visible, but the point-of-care sector was always significant, even before the pandemic. Point-of-care markets (and the companies that served them) grew faster than other markets.
January 3, 2022
Natera touts data supporting personalized ctDNA testing
The data were presented at the virtual European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer, which was held from July 1 to 4, and support the validity of Natera's Signatera ctDNA test for identifying molecular residual disease in patients with this type of cancer. The test is customized for each individual, based on the clonal mutations in his or her tumor, according to the company.
July 6, 2020
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
More stool PCR testing likely needed in COVID-19 patients
COVID-19 is commonly seen as a respiratory disease and much of the focus for diagnosis and also discharge of patients from hospitals following recovery has understandably been on the status of respiratory specimens. But gastrointestinal symptoms are also part of the disease and deserve more attention to help "prevent further spread of this highly contagious pathogen," wrote Dr. Sravanthi Parasa, a gastroenterologist at Swedish Medical Center in Seattle, and colleagues.
June 11, 2020
Jury is still out on SARS-CoV-2 intermediate host
One researcher from the University of Ottawa provides genomic evidence that dogs may be an intermediate carrier, while another study from Chinese researchers suggests that canines would be a poor transmitter of the virus.
April 16, 2020
Meridian acquires GenePOC from Debiopharm
Through the deal, Meridian will gain GenePOC's revogene product for microbial testing, which incorporates polymerase chain reaction (PCR) techniques for rapid testing in cases where infectious diseases are suspected. The product is marketed in the U.S., Europe, and Canada.
April 30, 2019
Page 1 of 1